drugset / Trial / NCT02972983
Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia
Phase 4
Completed
102 enrolled
McGill University Health Centre/Research Institute of the McGill University Health Centre
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of our study is to examine the effects of a second antibiotic, daptomycin, in combination with a beta lactam antibiotic on treating bloodstream infection caused by methicillin-susceptible S. aureus.
Timeline
- Start
- 2016-12-01
- Primary completion
- 2019-07
- Completion
- 2019-09
Publications
- Background Cheng MP, Lawandi A, Butler-Laporte G, Paquette K, Lee TC. Daptomycin versus placebo as an adjunct to beta-lactam therapy in the treatment of Staphylococcus aureus bacteremia: study protocol for a randomized controlled trial. Trials. 2018 May 29;19(1):297. doi: 10.1186/s13063-018-2668-6.
- Background Cheng MP, Lawandi A, Butler-Laporte G, De l'Etoile-Morel S, Paquette K, Lee TC. Adjunctive Daptomycin in the Treatment of Methicillin-susceptible Staphylococcus aureus Bacteremia: A Randomized, Controlled Trial. Clin Infect Dis. 2021 May 4;72(9):e196-e203. doi: 10.1093/cid/ciaa1000.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daptomycin | Other / unclassified | — | Intravenous |